Serum CGRP in migraine patients using erenumab as preventive treatment

Simone de Vries Lentsch; Ingrid M. Garrelds; A. H.Jan Danser; Gisela M. Terwindt; Antoinette MaassenVanDenBrink

doi:10.1186/s10194-022-01483-z

Serum CGRP in migraine patients using erenumab as preventive treatment

Simone de Vries Lentsch, Ingrid M. Garrelds, A. H.Jan Danser, Gisela M. Terwindt, Antoinette MaassenVanDenBrink^*

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

31 Downloads (Pure)

Abstract

AIM: Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. METHODS: Blood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. RESULTS: Serum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24). CONCLUSION: Lower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.

Original language	English
Article number	120
Journal	The journal of headache and pain
Volume	23
Issue number	1
DOIs	https://doi.org/10.1186/s10194-022-01483-z
Publication status	Published - Dec 2022

Bibliographical note

Funding Information:
This study was supported by Vici grant 09150181910040 from the Dutch Research Council (AMVDB).

Funding Information:
Gisela Terwindt reports consultancy support from Allergan/Abbvie, Lilly, Lundbeck, Novartis, and Teva, and independent support from Dutch Organization for Scientific Research, the Dutch Heart & Brain Foundations, IRRF and Dioraphte. Antoinette MaassenVanDenBrink reports consultancy or industry grant support from Novartis, Lilly and Teva, and independent support from the Dutch Research Council and the Dutch Heart & Brain Foundations. Simone de Vries Lentsch, Ingrid Garrelds and Jan Danser have nothing to disclose.

Publisher Copyright:
© 2022, The Author(s).

Access to Document

10.1186/s10194-022-01483-zLicence: CC BY

s10194-022-01483-zFinal published version, 1.07 MBLicence: CC BY

Cite this

@article{3057137a817b4c2d83c6b9e1a4d2d4a4,

title = "Serum CGRP in migraine patients using erenumab as preventive treatment",

abstract = "AIM: Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. METHODS: Blood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. RESULTS: Serum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24). CONCLUSION: Lower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.",

author = "{de Vries Lentsch}, Simone and Garrelds, {Ingrid M.} and Danser, {A. H.Jan} and Terwindt, {Gisela M.} and Antoinette MaassenVanDenBrink",

note = "Funding Information: This study was supported by Vici grant 09150181910040 from the Dutch Research Council (AMVDB). Funding Information: Gisela Terwindt reports consultancy support from Allergan/Abbvie, Lilly, Lundbeck, Novartis, and Teva, and independent support from Dutch Organization for Scientific Research, the Dutch Heart & Brain Foundations, IRRF and Dioraphte. Antoinette MaassenVanDenBrink reports consultancy or industry grant support from Novartis, Lilly and Teva, and independent support from the Dutch Research Council and the Dutch Heart & Brain Foundations. Simone de Vries Lentsch, Ingrid Garrelds and Jan Danser have nothing to disclose. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s10194-022-01483-z",

language = "English",

volume = "23",

journal = "The journal of headache and pain",

issn = "1129-2369",

publisher = "Springer-Verlag Italia",

number = "1",

}

TY - JOUR

T1 - Serum CGRP in migraine patients using erenumab as preventive treatment

AU - de Vries Lentsch, Simone

AU - Garrelds, Ingrid M.

AU - Danser, A. H.Jan

AU - Terwindt, Gisela M.

AU - MaassenVanDenBrink, Antoinette

N1 - Funding Information: This study was supported by Vici grant 09150181910040 from the Dutch Research Council (AMVDB). Funding Information: Gisela Terwindt reports consultancy support from Allergan/Abbvie, Lilly, Lundbeck, Novartis, and Teva, and independent support from Dutch Organization for Scientific Research, the Dutch Heart & Brain Foundations, IRRF and Dioraphte. Antoinette MaassenVanDenBrink reports consultancy or industry grant support from Novartis, Lilly and Teva, and independent support from the Dutch Research Council and the Dutch Heart & Brain Foundations. Simone de Vries Lentsch, Ingrid Garrelds and Jan Danser have nothing to disclose. Publisher Copyright: © 2022, The Author(s).

PY - 2022/12

Y1 - 2022/12

N2 - AIM: Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. METHODS: Blood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. RESULTS: Serum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24). CONCLUSION: Lower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.

AB - AIM: Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab were measured to evaluate the association with clinical treatment response. METHODS: Blood samples were collected from the cubital fossa before (T0) and 2-4 weeks after (T1) starting treatment with erenumab. Clinical response was monitored using a daily headache e-diary. Serum levels of CGRP-LI, assessed using radioimmunoassay, were compared between T0 and T1, correcting for migraine reduction. In addition, for both T0 and T1, linear regression models were constructed using migraine reduction as outcome and serum CGRP-LI as independent variable, corrected for age, gender and monthly migraine days (MMD) at baseline. RESULTS: Serum CGRP-LI did not differ between T0 and T1 (p = 0.30). However, there was an interaction between time and reduction in MMD (p = 0.01). Absolute reduction in MMD in the third month after treatment with erenumab was associated with serum CGRP-LI at T1, 2-4 weeks after starting treatment with erenumab (p = 0.003), but not with serum CGRP-LI at T0 (p = 0.24). CONCLUSION: Lower serum CGRP-LI 2-4 weeks after starting treatment with erenumab was associated with a higher reduction in migraine days after three months of treatment. Although the underlying mechanisms remain to be determined, this suggests that changes in CGRP levels, shortly after starting erenumab, are important for its clinical effect.

UR - http://www.scopus.com/inward/record.url?scp=85137743179&partnerID=8YFLogxK

U2 - 10.1186/s10194-022-01483-z

DO - 10.1186/s10194-022-01483-z

M3 - Article

C2 - 36089587

AN - SCOPUS:85137743179

SN - 1129-2369

VL - 23

JO - The journal of headache and pain

JF - The journal of headache and pain

IS - 1

M1 - 120

ER -

Serum CGRP in migraine patients using erenumab as preventive treatment

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this